News of Israeli medicine

♦ Tazemetostat was approved by FDA for the treatment of epithelioid sarcoma. (04/02/2020)

♦ FoundationOne CDx Ovarian Cancer testing checks an effectiveness of Lynparza targeted therapy. (11/09/2019)

♦ A family history of melanoma increases your risk of skin cancer by up to 74%. (22/08/2019)

♦ Molecular testing for prostate cancer in Israel. (30/07/2019)

♦ Onco tests for Thyroid Cancer in Israel. (23/07/2019)

♦ Review – Oncotests used in Israel. (24/06/2019)

♦ Medullary thyroid cancer. Rare type of cancer treatment in Israel. (09/06/2019)

♦ Oncotest Teva Guardant 360 Liquid Biopsy – mutations test for all cancer types by blood analysis. (22/05/2019)

♦ CAR-T therapy in Israel: treatment of multiple myeloma, acute leukemia and lymphoma has become more accessible. (29/04/2019)

♦ Praluent (alirocumab) reduces mortality for atherosclerotic cardiovascular diseases (ASCVD). (23/04/2019)

♦ Precancerous conditions and lesions – diagnostics and treatment in Israel. (17/04/2019)

♦ Atezolizumab as a first line treatment for triple negative breast cancer. (13/03/2019)

♦ Resume – the latest achievements and successful cancer treatment strategies in Israel and the world in 2018. (21/02/2019)

♦ mFOLFIRINOX – significant survival increase in pancreatic carcinoma treatment. (05/02/2019)

♦ Test for tuberculosis (TB) before surgery in Israel – new requirements of Israeli clinics. (27/01/2019)

♦ Papillary carcinoma of the thyroid (PTC) treatment in Israel. (24/01/2019)

♦ LDH analysis for melanoma treatment prognosis – study. (21/01/2019)

♦ Non Small Cell Lung Cancer (NSCLC) – modern treatment methods in Israel. (15/12/2018)

♦ New vaccinations requirements before treatment in Israel. (15/11/2018)

♦ Oncogenetic counseling in Israel. Gene mutation detection and treatment.  (06/03/2018)

♦ Last stage cancer treatment in Israel. (06/02/2018)

♦ Leading Israeli surgeon answers questions about legs osteoarthritis.

♦ Nasal septum cells could help repair gamaged knee cartilage.